Acadian Asset Management LLC Has $1.19 Million Stock Holdings in Travere Therapeutics, Inc. (NASDAQ:TVTX)

Acadian Asset Management LLC boosted its stake in shares of Travere Therapeutics, Inc. (NASDAQ:TVTX) by 202.6% in the 2nd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 144,901 shares of the company’s stock after buying an additional 97,020 shares during the quarter. Acadian Asset Management LLC owned approximately 0.19% of Travere Therapeutics worth $1,190,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. EntryPoint Capital LLC bought a new position in shares of Travere Therapeutics in the first quarter valued at approximately $32,000. China Universal Asset Management Co. Ltd. boosted its holdings in Travere Therapeutics by 68.6% in the first quarter. China Universal Asset Management Co. Ltd. now owns 14,652 shares of the company’s stock valued at $113,000 after acquiring an additional 5,962 shares in the last quarter. Dynamic Technology Lab Private Ltd bought a new stake in Travere Therapeutics in the fourth quarter valued at $137,000. SG Americas Securities LLC bought a new stake in shares of Travere Therapeutics during the 2nd quarter valued at $139,000. Finally, ProShare Advisors LLC boosted its holdings in shares of Travere Therapeutics by 9.2% during the 1st quarter. ProShare Advisors LLC now owns 18,421 shares of the company’s stock valued at $142,000 after buying an additional 1,557 shares in the last quarter.

Insider Activity at Travere Therapeutics

In other news, CEO Eric M. Dube sold 21,125 shares of the stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $11.52, for a total value of $243,360.00. Following the completion of the sale, the chief executive officer now owns 361,975 shares of the company’s stock, valued at approximately $4,169,952. The transaction was disclosed in a filing with the SEC, which is accessible through this link. In other Travere Therapeutics news, CEO Eric M. Dube sold 21,125 shares of Travere Therapeutics stock in a transaction dated Monday, September 9th. The shares were sold at an average price of $11.52, for a total transaction of $243,360.00. Following the completion of the transaction, the chief executive officer now owns 361,975 shares in the company, valued at $4,169,952. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, SVP William E. Rote sold 4,387 shares of the business’s stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $11.52, for a total transaction of $50,538.24. Following the completion of the sale, the senior vice president now owns 84,455 shares of the company’s stock, valued at $972,921.60. The disclosure for this sale can be found here. Insiders sold 30,707 shares of company stock valued at $352,712 in the last three months. 3.75% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on the stock. Bank of America upped their price target on shares of Travere Therapeutics from $18.00 to $19.00 and gave the company a “buy” rating in a research report on Friday, September 6th. Wedbush lifted their target price on Travere Therapeutics from $13.00 to $16.00 and gave the company an “outperform” rating in a research note on Friday, August 2nd. Canaccord Genuity Group upped their target price on Travere Therapeutics from $18.00 to $23.00 and gave the stock a “buy” rating in a research note on Tuesday, September 10th. Barclays increased their price target on Travere Therapeutics from $12.00 to $14.00 and gave the stock an “overweight” rating in a report on Friday, August 2nd. Finally, Citigroup raised their price target on Travere Therapeutics from $14.00 to $23.00 and gave the stock a “buy” rating in a research note on Friday, September 6th. Four investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $17.58.

Travere Therapeutics Stock Performance

Shares of Travere Therapeutics stock opened at $13.48 on Monday. The company has a quick ratio of 2.99, a current ratio of 3.04 and a debt-to-equity ratio of 24.96. The company has a fifty day moving average of $9.68 and a 200-day moving average of $7.99. Travere Therapeutics, Inc. has a 52-week low of $5.12 and a 52-week high of $14.07.

Travere Therapeutics (NASDAQ:TVTX) last posted its quarterly earnings data on Thursday, August 1st. The company reported ($0.90) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.87) by ($0.03). The business had revenue of $54.12 million during the quarter, compared to analysts’ expectations of $49.50 million. Travere Therapeutics had a negative return on equity of 269.18% and a negative net margin of 82.14%. Equities analysts forecast that Travere Therapeutics, Inc. will post -3.96 EPS for the current fiscal year.

Travere Therapeutics Profile

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.